Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: CPAMarty who wrote (57)	2/4/1999 8:57:00 PM
From: BRAVEHEART	Respond to of 423

Hi JMARCUS, Thanks for answering many of the key considerations with respect to SUNP. While I will follow it in my own way please keep us up to date on any significant developments you anticipate as they approach. Clearly the more indications the cancer product is successful with the better. Let's hope for steller results. The fact that it is a multi trial does reduce risk somewhat. BEST WISHES LONE WOLF

To: CPAMarty who wrote (57)	2/4/1999 9:15:00 PM
From: BRAVEHEART	Read Replies (2) \| Respond to of 423

Hi Marty, I was looking at the three companies which tanked on that day. Interesting comparison. The same market so it helps clarify what transpired. NRGN and VRTX both had a bounce. CLPA did not. I am skeptical when an analyst comes out with a price projection soon after a significant development. With SCIO on Mon morning an analyst came out with a fair valuation story. Funny how 1,000,000 shares had to cover yet. Do you think this story helped their position. biz.yahoo.com quote.yahoo.com Look at the trading pattern of CLPA NRGN and VRTX. quote.yahoo.com Funny the story which tied the three together. Drug setbacks sink Cell Pathways, Vertex, Neurogen: Had this to say about CLPA. The company said clinical tests on Prevatac, developed to treat the genetic disease that leads to colon cancer, failed to yield the desired results needed to apply for the drug's federal approval. The setback may delay the drug's introduction by between 12 and 24 months, and curtail Cell Pathway's revenues, Janney Montgomery Scott analyst Heather Morris said. ''Because this trial failed to show statistical significance, it clearly pushes the time line on this company way out into the future, and it adds uncertainty,'' she said. She cut her rating on the shares to hold from buy and slashed her 12-month price target to $10 from $31. Hmmm I don't think CLPA was the one to buy on Tue. I wonder if the story helped anyone exit at $9. Actually NRGN appears to have received the greatest market sentiment. I intend on looking at all three companies more closely. My guess is CLPA is the least promising based on market reaction. Not to say that once it finds a bottom that it couldn't prove to be a buy. BEST WISHES LONE WOLF